ACTRN12612000259842
Not Yet Recruiting
Phase 4
Immunogenicity of Combined Bivalent OPV and IPV Vaccines at 9 - 12 months of Age Compared to bOPV alone in Malnourished and Non-Malnourished Pakistani Infants, Aga Khan University, Karachi Pakistan
WHO0 sites840 target enrollmentMarch 2, 2012
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- polio vaccine immunogenecity
- Sponsor
- WHO
- Enrollment
- 840
- Status
- Not Yet Recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Infant aged 9 \- 12 months of age
- •Resident of the study area for last 3 month at the time of enrolment
- •Parent/guardian provides informed consent
- •Nutritional status will be assessed; chronically malnourished children and normally nourished children will be assigned to different study arms
Exclusion Criteria
- •Infant already enrolled in any other polio intervention study.
- •Allergic to antibiotics neomycin, streptomycin or polymyxin B (as these antibiotics are the component of IPV and may lead to severe life\-threatening events)
- •Infant found acutely ill at the time of enrolment, requiring emergent medical care
- •Infant with moderate and severe acute malnutrition, defined by a very low weight for height (below \-2z and \-3z scores of the median WHO growth standards respectively).
- •Refusal of blood testing
- •Receipt of supplementary dose of OPV within 4 weeks of first study visit
- •Infant with certain medical conditions i.e., cerebral palsy, syndromic infants, infants on corticosteroids because of any medical illness, thrombocytopenia (contraindication of intramuscular injections), malignancies and infant with primary immunodeficiency
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not Yet Recruiting
N/A
Immunogenicity of oral polio vaccine in different doses in MozambiquepoliomyelitisInfection - Other infectious diseasesACTRN12619000184178WHO360
Completed
N/A
Brazilian pentavalent vaccineISRCTN95974322Bio-Manguinhos/Fiocruz (Brazil)1,200
Completed
N/A
Comparative evaluation of Immunogenicity of monovalent type 1 Oral Poliovirus Vaccine (mOPV1) and monovalent type 3 Oral Poliovirus Vaccine (mOPV3) versus trivalent Oral Poliovirus Vaccine (tOPV): a randomised double-blind controlled trial in South AfricaPoliomyelitisInfections and InfestationsISRCTN18107202World Health Organization (WHO) (Switzerland)800
Completed
N/A
Comparative evaluation of immunogenicity of monovalent type 1 oral poliovirus vaccine (mOPV1) versus trivalent OPV (tOPV): a randomised double-blind trial set in EgyptPolioInfections and InfestationsISRCTN76316509World Health Organization (WHO) (Switzerland)600
Not Yet Recruiting
Phase 1
Safety and immune response of polio vaccines in healthy adultsACTRN12612000465853World Health Organization30